Epidermal Growth Factor Receptor Inhibitor-Induced Symmetrical Drug-Related Intertriginous and Flexural Exanthema: Should You Discontinue the Offending Agent?
January 2023
in “
Cutis
”
TLDR You might not need to stop cancer treatment if you get a rare skin reaction from EGFR inhibitors, as skin treatments can help manage it.
Epidermal growth factor receptor (EGFR) inhibitors are known to cause various skin adverse events, including alopecia. Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) is a rare skin reaction to EGFR inhibitors, and there is no established treatment protocol. The document presents two cases where patients with SDRIFE continued their EGFR inhibitor therapy while receiving topical treatments to manage symptoms. A review of the literature on SDRIFE related to EGFR inhibitors indicates that dermatologists play a vital role in diagnosing and managing this condition. The findings suggest that skin-directed therapy can be effective, and it may not be necessary to stop the cancer treatment due to SDRIFE.
